Trials / Withdrawn
WithdrawnNCT00162513
Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
Donors with CM will be solicited from a waiting list of patients awaiting BMT from the waiting list of MUD searches. Maximally matched donor will be searched for each eligible CML patient with a goal in mind to find other patients with CML that share both class I and class II determinants. Sharing of one class I II will be considered eligible for participation in the study. Peripheral blood and PBMC from the donors will be isolated, washed and irradiated. The cells will be injected into the consenting patients intracutaneously at 2 weeks intervals for a total of 6 injections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Allogeneic tumor cell vaccine |
Timeline
- Start date
- 2006-12-01
- First posted
- 2005-09-13
- Last updated
- 2011-04-28
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00162513. Inclusion in this directory is not an endorsement.